Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Plus: Niraparib Maintenance After 3 vs. 6 Cycles of Chemotherapy in Advanced Ovarian Cancer
NCT05460000Phase 2Recruiting
- Sponsor
- NOGGO
- Start
- Oct 2024
- Primary completion
- Oct 2032
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
A Phase 2 trial of niraparib, carboplatin, paclitaxel in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), clear cell carcinoma (CCC), sponsored by NOGGO. Started Oct 2024; status: recruiting.
02
Drugs
niraparibcarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT05460000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460000.